全文获取类型
收费全文 | 3048篇 |
免费 | 291篇 |
国内免费 | 6篇 |
出版年
2023年 | 23篇 |
2022年 | 17篇 |
2021年 | 76篇 |
2020年 | 29篇 |
2019年 | 39篇 |
2018年 | 61篇 |
2017年 | 47篇 |
2016年 | 68篇 |
2015年 | 149篇 |
2014年 | 135篇 |
2013年 | 201篇 |
2012年 | 267篇 |
2011年 | 248篇 |
2010年 | 136篇 |
2009年 | 114篇 |
2008年 | 171篇 |
2007年 | 153篇 |
2006年 | 167篇 |
2005年 | 119篇 |
2004年 | 110篇 |
2003年 | 101篇 |
2002年 | 103篇 |
2001年 | 89篇 |
2000年 | 76篇 |
1999年 | 62篇 |
1998年 | 22篇 |
1997年 | 24篇 |
1996年 | 30篇 |
1995年 | 31篇 |
1994年 | 22篇 |
1993年 | 12篇 |
1992年 | 38篇 |
1991年 | 20篇 |
1990年 | 38篇 |
1989年 | 35篇 |
1988年 | 30篇 |
1987年 | 19篇 |
1986年 | 22篇 |
1985年 | 30篇 |
1984年 | 14篇 |
1983年 | 17篇 |
1982年 | 16篇 |
1980年 | 17篇 |
1979年 | 25篇 |
1978年 | 10篇 |
1977年 | 10篇 |
1975年 | 14篇 |
1973年 | 10篇 |
1970年 | 10篇 |
1969年 | 12篇 |
排序方式: 共有3345条查询结果,搜索用时 171 毫秒
991.
Statistically quantified measurement of an Alzheimer's marker by surface‐enhanced Raman scattering 下载免费PDF全文
Ričardas Buividas Nerijus Dzingelevičius Reda Kubiliūtė Paul R. Stoddart Vi Khanh Truong Elena P. Ivanova Saulius Juodkazis 《Journal of biophotonics》2015,8(7):567-574
Fibrillar forms of the Amyloid‐β (Aβ) protein have been implicated in the early stages of Alzheimer's disease (AD), however there are no standardised assays for soluble Aβ oligomer biomarkers that provide the best indication of the disease progression [1,2]. As a step towards a fast and label‐free method for testing different AD biomarkers, we have combined laser nano‐textured substrates with a SERS mapping technique and validated it using soluble Aβ‐40 oligomers [3‐5]. The nano‐textured SERS substrates provide fast (&5 min), label‐free spectra associated with soluble Aβ‐40 oligomers down to a concentration of 10 nM. Statistical analysis of the spectral intensities mapped over the substrate surface shows a quantitative correlation with the oligomer concentration.
992.
Translocation of botulinum neurotoxin serotype A and associated proteins across the intestinal epithelia 下载免费PDF全文
Tina I. Lam Larry H. Stanker Kwangkook Lee Rongsheng Jin Luisa W. Cheng 《Cellular microbiology》2015,17(8):1133-1143
Botulinum neurotoxins (BoNTs) are some of the most poisonous natural toxins. Botulinum neurotoxins associate with neurotoxin‐associated proteins (NAPs) forming large complexes that are protected from the harsh environment of the gastrointestinal tract. However, it is still unclear how BoNT complexes as large as 900 kDa traverse the epithelial barrier and what role NAPs play in toxin translocation. In this study, we examined the transit of BoNT serotype A (BoNT/A) holotoxin, complex and recombinantly purified NAP complex through cultured and polarized Caco‐2 cells and, for the first time, in the small mouse intestine. Botulinum neurotoxin serotype A and NAPs in the toxin complex were detectable inside intestinal cells beginning at 2 h post intoxication. Appearance of the BoNT/A holotoxin signal was slower, with detection starting at 4–6 h. This indicated that the holotoxin alone was sufficient for entry but the presence of NAPs enhanced the rate of entry. Botulinum neurotoxin serotype A detection peaked at approximately 6 and 8 h for complex and holotoxin, respectively, and thereafter began to disperse with some toxin remaining in the epithelia after 24 h. Purified HA complexes alone were also internalized and followed a similar time course to that of BoNT/A complex internalization. However, recombinant HA complexes did not enhance BoNT/A holotoxin entry in the absence of a physical link with BoNT/A. We propose a model for BoNT/A toxin complex translocation whereby toxin complex entry is facilitated by NAPs in a receptor‐mediated mechanism. Understanding the intestinal uptake of BoNT complexes will aid the development of new measures to prevent or treat oral intoxications. 相似文献
993.
994.
995.
Shuhei Kusano Shogo Ishiyama Sik Lok Lam Tsukasa Mashima Masato Katahira Kengo Miyamoto Misako Aida Fumi Nagatsugi 《Nucleic acids research》2015,43(16):7717-7730
DNA interstrand crosslinks (ICLs) are the primary mechanism for the cytotoxic activity of many clinical anticancer drugs, and numerous strategies for forming ICLs have been developed. One such method is using crosslink-forming oligonucleotides (CFOs). In this study, we designed a 4-amino-6-oxo-2-vinylpyrimidine (AOVP) derivative with an acyclic spacer to react selectively with guanine. The AOVP CFO exhibited selective crosslinking reactivity with guanine and thymine in DNA, and with guanine in RNA. These crosslinking reactions with guanine were accelerated in the presence of CoCl2, NiCl2, ZnCl2 and MnCl2. In addition, we demonstrated that the AOVP CFO was reactive toward 8-oxoguanine opposite AOVP in the duplex DNA. The structural analysis of each guanine and 8-oxoguanine adduct in the duplex DNA was investigated by high-resolution NMR. The results suggested that AOVP reacts at the N2 amine in guanine and at the N1 or N2 amines in 8-oxoguanine in the duplex DNA. This study demonstrated the first direct determination of the adduct structure in duplex DNA without enzyme digestion. 相似文献
996.
Jian Xu Manavi Chatterjee Tyler D. Baguley Jonathan Brouillette Pradeep Kurup Debolina Ghosh Jean Kanyo Yang Zhang Kathleen Seyb Chimezie Ononenyi Ethan Foscue George M. Anderson Jodi Gresack Gregory D. Cuny Marcie A. Glicksman Paul Greengard TuKiet T. Lam Lutz Tautz Angus C. Nairn Jonathan A. Ellman Paul J. Lombroso 《PLoS biology》2014,12(8)
STEP (STriatal-Enriched protein tyrosine Phosphatase) is a neuron-specific phosphatase that regulates N-methyl-D-aspartate receptor (NMDAR) and α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPAR) trafficking, as well as ERK1/2, p38, Fyn, and Pyk2 activity. STEP is overactive in several neuropsychiatric and neurodegenerative disorders, including Alzheimer''s disease (AD). The increase in STEP activity likely disrupts synaptic function and contributes to the cognitive deficits in AD. AD mice lacking STEP have restored levels of glutamate receptors on synaptosomal membranes and improved cognitive function, results that suggest STEP as a novel therapeutic target for AD. Here we describe the first large-scale effort to identify and characterize small-molecule STEP inhibitors. We identified the benzopentathiepin 8-(trifluoromethyl)-1,2,3,4,5-benzopentathiepin-6-amine hydrochloride (known as TC-2153) as an inhibitor of STEP with an IC50 of 24.6 nM. TC-2153 represents a novel class of PTP inhibitors based upon a cyclic polysulfide pharmacophore that forms a reversible covalent bond with the catalytic cysteine in STEP. In cell-based secondary assays, TC-2153 increased tyrosine phosphorylation of STEP substrates ERK1/2, Pyk2, and GluN2B, and exhibited no toxicity in cortical cultures. Validation and specificity experiments performed in wild-type (WT) and STEP knockout (KO) cortical cells and in vivo in WT and STEP KO mice suggest specificity of inhibitors towards STEP compared to highly homologous tyrosine phosphatases. Furthermore, TC-2153 improved cognitive function in several cognitive tasks in 6- and 12-mo-old triple transgenic AD (3xTg-AD) mice, with no change in beta amyloid and phospho-tau levels. 相似文献
997.
Thomas Callender Mark Woodward Gregory Roth Farshad Farzadfar Jean-Christophe Lemarie Stéphanie Gicquel John Atherton Shadi Rahimzadeh Mehdi Ghaziani Maaz Shaikh Derrick Bennett Anushka Patel Carolyn S. P. Lam Karen Sliwa Antonio Barretto Bambang Budi Siswanto Alejandro Diaz Daniel Herpin Henry Krum Thomas Eliasz Anna Forbes Alastair Kiszely Rajit Khosla Tatjana Petrinic Devarsetty Praveen Roohi Shrivastava Du Xin Stephen MacMahon John McMurray Kazem Rahimi 《PLoS medicine》2014,11(8)
Background
Heart failure places a significant burden on patients and health systems in high-income countries. However, information about its burden in low- and middle-income countries (LMICs) is scant. We thus set out to review both published and unpublished information on the presentation, causes, management, and outcomes of heart failure in LMICs.Methods and Findings
Medline, Embase, Global Health Database, and World Health Organization regional databases were searched for studies from LMICs published between 1 January 1995 and 30 March 2014. Additional unpublished data were requested from investigators and international heart failure experts. We identified 42 studies that provided relevant information on acute hospital care (25 LMICs; 232,550 patients) and 11 studies on the management of chronic heart failure in primary care or outpatient settings (14 LMICs; 5,358 patients). The mean age of patients studied ranged from 42 y in Cameroon and Ghana to 75 y in Argentina, and mean age in studies largely correlated with the human development index of the country in which they were conducted (r = 0.71, p<0.001). Overall, ischaemic heart disease was the main reported cause of heart failure in all regions except Africa and the Americas, where hypertension was predominant. Taking both those managed acutely in hospital and those in non-acute outpatient or community settings together, 57% (95% confidence interval [CI]: 49%–64%) of patients were treated with angiotensin-converting enzyme inhibitors, 34% (95% CI: 28%–41%) with beta-blockers, and 32% (95% CI: 25%–39%) with mineralocorticoid receptor antagonists. Mean inpatient stay was 10 d, ranging from 3 d in India to 23 d in China. Acute heart failure accounted for 2.2% (range: 0.3%–7.7%) of total hospital admissions, and mean in-hospital mortality was 8% (95% CI: 6%–10%). There was substantial variation between studies (p<0.001 across all variables), and most data were from urban tertiary referral centres. Only one population-based study assessing incidence and/or prevalence of heart failure was identified.Conclusions
The presentation, underlying causes, management, and outcomes of heart failure vary substantially across LMICs. On average, the use of evidence-based medications tends to be suboptimal. Better strategies for heart failure surveillance and management in LMICs are needed. Please see later in the article for the Editors'' Summary 相似文献998.
Eugenia Corrales-Aguilar Mirko Trilling Katja Hunold Manuela Fiedler Vu Thuy Khanh Le Henrike Reinhard Katrin Ehrhardt Eva Mercé-Maldonado Enver Aliyev Albert Zimmermann David C. Johnson Hartmut Hengel 《PLoS pathogens》2014,10(5)
Human cytomegalovirus (HCMV) establishes lifelong infection with recurrent episodes of virus production and shedding despite the presence of adaptive immunological memory responses including HCMV immune immunoglobulin G (IgG). Very little is known how HCMV evades from humoral and cellular IgG-dependent immune responses, the latter being executed by cells expressing surface receptors for the Fc domain of IgG (FcγRs). Remarkably, HCMV expresses the RL11-encoded gp34 and UL119-118-encoded gp68 type I transmembrane glycoproteins which bind Fcγ with nanomolar affinity. Using a newly developed FcγR activation assay, we tested if the HCMV-encoded Fcγ binding proteins (HCMV FcγRs) interfere with individual host FcγRs. In absence of gp34 or/and gp68, HCMV elicited a much stronger activation of FcγRIIIA/CD16, FcγRIIA/CD32A and FcγRI/CD64 by polyclonal HCMV-immune IgG as compared to wildtype HCMV. gp34 and gp68 co-expression culminates in the late phase of HCMV replication coinciding with the emergence of surface HCMV antigens triggering FcγRIII/CD16 responses by polyclonal HCMV-immune IgG. The gp34- and gp68-dependent inhibition of HCMV immune IgG was fully reproduced when testing the activation of primary human NK cells. Their broad antagonistic function towards FcγRIIIA, FcγRIIA and FcγRI activation was also recapitulated in a gain-of-function approach based on humanized monoclonal antibodies (trastuzumab, rituximab) and isotypes of different IgG subclasses. Surface immune-precipitation showed that both HCMV-encoded Fcγ binding proteins have the capacity to bind trastuzumab antibody-HER2 antigen complexes demonstrating simultaneous linkage of immune IgG with antigen and the HCMV inhibitors on the plasma membrane. Our studies reveal a novel strategy by which viral FcγRs can compete for immune complexes against various Fc receptors on immune cells, dampening their activation and antiviral immunity. 相似文献
999.
1000.
Tieneke B.M. Schaaij-Visser Meike de Wit Siu W. Lam Connie R. Jiménez 《Biochimica et Biophysica Acta - Proteins and Proteomics》2013,1834(11):2242-2258
Despite major improvements on the knowledge and clinical management, cancer is still a deadly disease. Novel biomarkers for better cancer detection, diagnosis and treatment prediction are urgently needed. Proteins secreted, shed or leaking from the cancer cell, collectively termed the cancer secretome, are promising biomarkers since they might be detectable in blood or other biofluids. Furthermore, the cancer secretome in part represents the tumor microenvironment that plays a key role in tumor promoting processes such as angiogenesis and invasion. The cancer secretome, sampled as conditioned medium from cell lines, tumor/tissue interstitial fluid or tumor proximal body fluids, can be studied comprehensively by nanoLC-MS/MS-based approaches. Here, we outline the importance of current cancer secretome research and describe the mass spectrometry-based analysis of the secretome. Further, we provide an overview of cancer secretome research with a focus on the three most common cancer types: lung, breast and colorectal cancer. We conclude that the cancer secretome research field is a young, but rapidly evolving research field. Up to now, the focus has mainly been on the discovery of novel promising secreted cancer biomarker proteins. An interesting finding that merits attention is that in cancer unconventional secretion, e.g. via vesicles, seems increased. Refinement of current approaches and methods and progress in clinical validation of the current findings are vital in order to move towards applications in cancer management. This article is part of a Special Issue entitled: An Updated Secretome. 相似文献